| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Shanghai Pharmaceuticals Holding Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥1.33 |
| 52 Week High | CN¥1.80 |
| 52 Week Low | CN¥1.18 |
| Beta | 0.22 |
| 11 Month Change | 0% |
| 3 Month Change | 1.53% |
| 1 Year Change | -25.28% |
| 33 Year Change | -24.00% |
| 5 Year Change | -22.76% |
| Change since IPO | -24.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1R | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -1.5% | 0.09% |
| 1Y | -25.3% | 0.8% | 3.1% |
Return vs Industry: S1R underperformed the German Healthcare industry which returned 0.8% over the past year.
Return vs Market: S1R underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| S1R volatility | |
|---|---|
| S1R Average Weekly Movement | 4.9% |
| Healthcare Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: S1R has not had significant price volatility in the past 3 months.
Volatility Over Time: S1R's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 48,164 | Bo Shen | www.sphchina.com |
Shanghai Pharmaceuticals Holding Co., Ltd. engages research, development, manufacture, distribution, and retailing of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemicals and biochemicals, Chinese medicines, healthcare products, and medical devices in various therapeutic areas, including digestive system, immune metabolism, motor neuron disease, endocrinology, cardiovascular, psychoneurotic, neoplasm, autoimmunity, systemic anti-infection, mental nerve, anti-tumor, oncology, respiratory system, nervous system, auto-immunity, hypertension, neuromyelitis, diabetes, anticholinesterase, polypeptide hormones uterine tonic, antihistamine, anti-inflammatory, anesthetic, immunomodulatory, antiviral, reflux esophagitis, analgesics, weight management, malignant peritoneal effusion, ulcerative colitis, myasthenia gravis, burn injury, anticoagulant, anti-epileptic, anticonvulsant, Alzheimer’s, and inflammatory bowel diseases.
Shanghai Pharmaceuticals Holding Co., Ltd Fundamentals Summary
| S1R fundamental statistics | |
|---|---|
| Market cap | €8.13b |
| Earnings (TTM) | €487.71m |
| Revenue (TTM) | €33.98b |
18.7x
P/E Ratio0.3x
P/S RatioIs S1R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1R income statement (TTM) | |
|---|---|
| Revenue | CN¥264.22b |
| Cost of Revenue | CN¥233.90b |
| Gross Profit | CN¥30.32b |
| Other Expenses | CN¥26.53b |
| Earnings | CN¥3.79b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | 1.02 |
| Gross Margin | 11.48% |
| Net Profit Margin | 1.44% |
| Debt/Equity Ratio | 65.5% |
How did S1R perform over the long term?
See historical performance and comparison